ArticleTherapeutic advances in medical oncology2026

A phase II study of DFP-14323, a non-specific immunomodulator, in combination with low-dose afatinib as first-line therapy for common

Hiroshige Yoshioka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.